The Future of Keloid Disease Diagnosis and Therapy
Lamont R Jones, MD, MIBA
Keloid disease (KD) is characterized by painful and itchy benign fibroproliferative tumors of the skin which result from injury in genetically predisposed individuals. KD has high recurrence rates and there has been little progress in treating KD, mainly due to an incomplete understanding of its pathogenesis.
The development of KD specific diagnostic and prognostic biomarkers has the potential to have significant clinical impact by identifying clinical subgroups and novel therapeutic targets. This presentation will describe how innovative spatial technology can be used to identify prognostic and diagnostic KD biomarkers in formalin fixed paraffin embedded tissue and their future use as novel therapeutic targets.